Semax Therapy: Complete Guide
Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in Russia and approved there for stroke and cognitive indications. It is not approved by the FDA for any use in the United States. Its mechanism work — increasing BDNF and TrkB expression in the brain — is well documented in preclinical studies, while its clinical trial literature is largely Russian-language and has not been independently replicated in English-language journals. In July 2026 an FDA advisory committee recommended Semax for the 503A bulks list; a recommendation is advisory and did not change its legal status.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
What is Semax?
What Is Semax?
Semax is a synthetic heptapeptide related to the adrenocorticotropic hormone fragment ACTH(4-10). FDA's Semax briefing document identifies Semax free base as H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, with Semax acetate evaluated as a related acetate salt. The peptide is primarily discussed in the literature as an intranasal neuroactive compound with proposed neuroprotective and nootropic effects.
Why Semax Is Different From Most Peptide Hubs
Semax has a meaningful mechanistic literature, especially in rat brain models involving BDNF, TrkB, gene expression, and experimental ischemia. The clinical evidence is much thinner. Human reports are largely Russian-language, older, small, or not independently replicated in English-language journals. That makes Semax a research-interest peptide, not a proven U.S. treatment for cognition, stroke recovery, migraine, or pain.
Current Status
Semax is registered in Russia as nasal drops, but it is not FDA-approved for any indication in the United States. FDA's July 2026 briefing document states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug, and that neither has a USP or NF drug substance monograph. On July 24, 2026, the FDA Pharmacy Compounding Advisory Committee voted to recommend Semax-related bulk drug substances (Semax free base and Semax acetate) for the 503A Bulks List. That recommendation is advisory only; it is not FDA approval and did not itself change what a patient can legally receive from a compounding pharmacy. FDA's own briefing materials had proposed that Semax free base and Semax acetate, along with the other six peptide families reviewed at the July 23–24 meeting, not be included. For this to affect routine patient access, FDA would still need to make a final determination and add the relevant bulk drug substance to the 503A Bulks List through notice-and-comment rulemaking.
How Semax Works
ACTH(4-10)-Related Signaling
Semax is described as a synthetic analog of the ACTH(4-10) fragment that is proposed to retain neurobehavioral activity without the full hormonal corticotropic and melanotropic activity associated with ACTH. FDA also noted that Semax is a common name rather than a USAN, INN, or IUPAC name, which matters because different forms can be marketed under the same common name.
BDNF and TrkB Pathway
Dolotov et al., Journal of Neurochemistry, 2006 reported that Semax bound specifically and increased brain-derived neurotrophic factor (BDNF) protein in rat basal forebrain. A companion Dolotov et al. study in Brain Research, 2006 found that a single intranasal Semax exposure in rats increased hippocampal BDNF protein, TrkB phosphorylation, BDNF mRNA, and TrkB mRNA. This is the strongest mechanistic basis for Semax's neurotrophic framing.
Gene-Expression Effects in Ischemia Models
Recent preclinical work continues to connect ACTH-like peptides to ischemia-related gene expression. Filippenkov et al., International Journal of Molecular Sciences, 2025 used rat ischemia-reperfusion transcriptomics and found that Semax and ACTH(6-9)PGP modulated gene-expression patterns in brain regions with different degrees of ischemic damage. This supports a plausible neuroprotection mechanism, but it remains animal-model evidence.
Other Proposed Pathways
FDA's review summarized additional nonclinical hypotheses, including antioxidant properties, modulation of ischemia-related gene expression, serotonergic signaling in antinociception models, and dopaminergic effects in rodents. These mechanisms are biologically interesting but do not establish clinical efficacy in humans.
Benefits & Uses
Potential Benefits Under Study
The benefits commonly associated with Semax should be read as research signals and clinical claims, not as established U.S. therapeutic effects.
- Neurotrophic signaling: Rat studies show modulation of BDNF and TrkB pathways after intranasal Semax exposure.
- Experimental neuroprotection: Animal ischemia models and transcriptomic studies suggest Semax can influence pathways involved in neuronal stress, inflammation, and recovery after ischemic injury.
- Cognitive effects: Rat studies report changes in conditioned avoidance learning, and older Russian-language human literature discusses memory and attention, but modern replicated human trials are lacking.
- Stroke-recovery interest: A Russian-language acute ischemic stroke study reported faster regression of neurologic deficits when Semax was added to intensive therapy, but this has not been validated in large modern trials.
- Migraine and trigeminal neuralgia claims: FDA reviewed these uses and concluded the evidence was insufficient.
What Has Not Been Established
Semax has not been shown in modern, well-controlled, English-language clinical trials to prevent stroke, improve post-stroke disability, treat migraine, treat trigeminal neuralgia, improve ADHD, or provide durable cognitive enhancement in healthy adults. The most honest Semax benefit claim is that its mechanistic rationale is stronger than its clinical proof.
Clinical Evidence & Research
Mechanistic and Preclinical Evidence
Dolotov et al., Journal of Neurochemistry, 2006 and Dolotov et al., Brain Research, 2006 provide the core mechanistic Semax evidence: specific binding, BDNF protein changes, TrkB activation, and neurotrophin gene-expression effects in rat brain regions after Semax exposure. Filippenkov et al., International Journal of Molecular Sciences, 2025 extends the preclinical picture into rat ischemia-reperfusion transcriptomics. These studies support plausibility, not clinical efficacy.
Acute Ischemic Stroke Study
Gusev et al., Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 1997 studied Semax in 30 patients during the acute period of hemispheric ischemic stroke, with an 80-patient conventional-therapy control group. The PubMed abstract reports improvement in the rate of neurological recovery, especially motor deficits, and identifies daily doses of 12 mg for moderate stroke and 18 mg for severe stroke over 5–10 days.
Why This Evidence Is Thin
The human evidence base is not comparable to the evidence base for approved GLP-1 drugs or FDA-approved peptide drugs. The key stroke study is Russian-language, older, and not replicated in large multicenter trials using contemporary endpoints such as modified Rankin Scale outcomes at 90 days. FDA's July 2026 presentation stated that multiple Russian-language references were not considered in its evaluation because full references were not available in English, and FDA concluded there was insufficient evidence of effectiveness for cerebral ischemia.
Migraine and Trigeminal Neuralgia
FDA's July 2026 review also evaluated migraine and trigeminal neuralgia. The agency described the relevant human evidence as a small, uncontrolled, open-label study with major limitations and concluded there was insufficient evidence to support Semax free base or Semax acetate for either migraine or trigeminal neuralgia.
Evidence Quality Summary
Preclinical evidence is plausible but disease-model dependent. Human evidence is limited, older, and largely Russian-language. There is no FDA approval, no U.S. prescribing label, and no established U.S. standard of care for Semax.
Side Effects & Safety
Safety Data Are Limited
Semax does not have a U.S. prescribing label, so there is no FDA-approved adverse-event table, contraindication list, or standardized monitoring plan. FDA's review concluded that there is insufficient clinical information to characterize the safety profile of Semax via the intranasal route, no safety data for the proposed subcutaneous route, and no published human pharmacokinetic studies.
Reported and Theoretical Concerns
- Nasal or ocular irritation: FDA noted a FAERS report involving eye pain and burning after use of Semax 0.1% nasal drops purchased online. A single FAERS report does not establish incidence, but it is a safety signal.
- Immunogenicity risk: FDA raised concerns about peptide aggregation and peptide-related impurities, especially for injectable or nasal spray formulations.
- Bleeding risk uncertainty: FDA noted that one reference discussing possible antithrombotic properties raised concern about bleeding risk, particularly in patients at risk for bleeding or using medications that increase bleeding risk.
- Dopaminergic effects: FDA summarized rodent findings in which Semax potentiated amphetamine-induced locomotor activity and striatal dopamine release, which creates uncertainty around neuropsychiatric effects.
- Quality risk: Products sold online or as research chemicals are not FDA-regulated drugs, and identity, potency, sterility, endotoxin control, and impurity profiles may not be reliable.
Unknowns
Long-term safety, pregnancy and breastfeeding effects, pediatric safety outside specific foreign-use contexts, drug interactions, abuse potential, and safety of repeated subcutaneous dosing are not well characterized in the allowed literature.
Dosing & Administration
No FDA-Approved Dosing
There is no FDA-approved Semax dose, dosing schedule, route, or product formulation in the United States. Semax should not be treated like a U.S.-approved prescription drug with a validated label.
Published Stroke-Study Dosing
The Gusev et al. acute ischemic stroke abstract reports daily Semax doses of 12 mg for moderate stroke and 18 mg for severe stroke, with treatment courses of 5 and 10 days. That study context was acute stroke intensive therapy, not outpatient nootropic use.
Marketplace Convention
U.S. clinic and vendor protocols usually present Semax as an intranasal spray or drops, sometimes alongside subcutaneous injection. FDA's nomination review described proposed Semax products as intranasal spray or subcutaneous injection at 7,500 mcg/mL or 1,000 mcg/mL strengths. Vendors commonly translate those concentrations into microgram-per-spray instructions and short cycles, but those are marketplace conventions.
Important Dosing Caveat
The cited Semax literature does not establish a validated intranasal microgram protocol for cognition, focus, migraine, or general neurorecovery. It also does not establish subcutaneous dosing. FDA specifically noted missing human pharmacokinetic data and missing safety data for the proposed subcutaneous route.
Find Semax Providers Near You
Browse 2 listed providers offering Semax therapy in our directory. Compare clinics by location, telehealth availability and insurance acceptance.
Browse ProvidersSemax FAQ
No. Semax is not FDA-approved for any indication in the United States. FDA states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug, and neither has a USP or NF drug substance monograph.
PCAC recommended Semax free base and Semax acetate for the 503A Bulks List on July 24, 2026, but the recommendation is advisory. It is not FDA approval and did not itself make compounded Semax lawful or available. FDA would still need to complete its own process and add the substance through rulemaking.
In rat studies, yes: Dolotov et al. reported BDNF and TrkB-related changes in basal forebrain and hippocampus after Semax exposure. That is mechanistic animal evidence, not proof that Semax produces clinically meaningful BDNF-driven benefits in humans.
No. The main human stroke evidence is older Russian-language literature, including a 1997 study in acute hemispheric ischemic stroke. The abstract reports improvement signals, but the evidence has not been replicated in large modern trials, and FDA concluded the evidence was insufficient for cerebral ischemia.
Clinic and vendor protocols commonly use intranasal spray or drops with microgram-per-spray instructions, and some market subcutaneous use. These are conventions, not validated dosing schedules. The cited stroke study used milligram daily dosing in acute stroke, and FDA noted missing human pharmacokinetic and subcutaneous safety data.
The true side-effect profile is not well characterized. FDA highlighted limited intranasal safety information, no proposed-route subcutaneous safety data, no human pharmacokinetic studies, possible immunogenicity concerns from impurities or aggregation, and a FAERS report involving eye pain and burning after online nasal-drop use.
What Semax is used for
Each of these reviews the evidence for that goal, including where it is weaker than the marketing suggests.
Where to get Semax with a prescription
Semax requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Stay Updated
Get notified when new peptide therapy providers join in your area.
Related Peptides
Sources
Primary literature, regulatory filings, and prescribing information behind this guide. External links open in a new tab.
- Dolotov OV et al., Semax binds specifically and increases BDNF protein in rat basal forebrain, J Neurochem 2006
- Dolotov OV et al., Semax regulates BDNF and TrkB expression in rat hippocampus, Brain Res 2006
- Gusev EI et al., Semax in acute hemispheric ischemic stroke, Zh Nevrol Psikhiatr 1997
- Filippenkov IB et al., ACTH-like peptides and ischemic brain-region gene expression, Int J Mol Sci 2025
- FDA PCAC meeting page and webcast links, July 23-24, 2026
- FDA briefing document for Semax-related bulk drug substances
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.